
TL;DR: An IgG food intolerance test measures food-specific antibodies, but a positive result alone does not establish that a food causes symptoms.
Key takeaways
- Food-specific immunoglobulin G (IgG) can reflect exposure to food rather than an adverse reaction, according to the Canadian Society of Allergy and Clinical Immunology's position statement.
- Food allergy and food intolerance are not interchangeable: the EAACI diagnosis guideline distinguishes immune-mediated allergy from non-immune-mediated intolerance.
- A 2025 randomised trial00328-2/fulltext) found a benefit from a specific IgG-guided diet in people with irritable bowel syndrome. That is not validation of every commercial food panel.
- mescreen™'s UAE product page describes a non-diagnostic mitochondrial function assessment, not a food intolerance investigation.
What does an IgG food intolerance test measure?
An IgG food intolerance test measures antibodies to foods, not a direct read-out of which foods are causing illness. The CSACI position statement explains that food-specific IgG may indicate exposure and tolerance, and that positive results occur in healthy adults and children.
The important distinction is between measuring something and establishing what that measurement means. Finding an antibody does not, by itself, demonstrate that the corresponding food explains a person's symptoms. The same position statement discourages using food-specific IgG to identify or predict adverse reactions to food.

A longer food list can look impressive. A menu is also a long food list, and nobody mistakes it for a diagnosis.
Is a food intolerance test the same as an allergy test?
No. Food intolerance and food allergy describe different mechanisms, and an IgG panel is not interchangeable with an allergy assessment. The European Academy of Allergy and Clinical Immunology's 2023 guideline defines food allergy as immune-mediated and food intolerance as non-immune-mediated.
Immunoglobulin E (IgE) is a different antibody from IgG. For suspected IgE-mediated food allergy, the EAACI guideline starts with an allergy-focused clinical history, followed by appropriate tests such as food-specific IgE or skin-prick testing. It recommends against using isolated IgG or IgG-subclass tests to diagnose IgE-mediated food allergy.
Even an IgE result needs context. The guideline's diagnostic approach combines the history and test findings, sometimes with a medically supervised oral food challenge, in which a clinician assesses a response to a food. This is not a home experiment or an instruction to try a suspected allergen.
Does newer research change the IgG picture?
Newer research suggests a possible role for a particular IgG-guided dietary intervention in irritable bowel syndrome (IBS), not a universal test for food intolerance. A 2025 randomised, sham-controlled trial in Gastroenterology00328-2/fulltext) studied a novel IBS-specific assay in 238 people with IBS; 223 were included in the modified intention-to-treat analysis.
In that trial's primary analysis00328-2/fulltext), 59.6% of the experimental-diet group and 42.1% of the sham-diet group met the specified abdominal-pain improvement endpoint. The endpoint required at least a 30% reduction in abdominal pain intensity during at least two of the final four treatment weeks. It was a symptom outcome, not proof of food allergy.

The distinction matters when research meets retail. The study tested a particular assay and dietary intervention in an IBS population. It did not establish that any large commercial IgG panel can diagnose the cause of symptoms in the general public. The paper also discloses industry funding00328-2/fulltext) from Biomerica and consultancy relationships for several authors, relevant context when weighing the findings.
The sensible reading is neither “every panel works” nor “there is no research”. It is “match the claim to the actual study”. Research has enough to do without moonlighting as a universal permission slip.
What should Dubai and Gulf readers ask before paying?
Ask what the test measures, what clinical question it answers and whether the evidence concerns the exact assay being sold. These are more useful comparison points than the number of foods included in a package.
For a UAE reader comparing a home-collection service with a clinic package, use this short evidence checklist:
- Measurement: Does the provider clearly distinguish IgG from IgE?
- Purpose: Is the claim about diagnosing an allergy, explaining symptoms or studying a specific intervention?
- Evidence: Does the cited study examine the same assay, patient group and intended use?
- Interpretation: Who explains the result, and how are the clinical history and limitations considered?
- Next steps: Is there a clinical review rather than an automatic list of foods to remove?

These questions follow the distinction between antibody findings and clinical assessment in the EAACI diagnostic guideline. They are purchasing questions, not a recommendation to buy or undergo a test.
For a different question about handling meals, our Dubai food-safety guide discusses the cold chain. Food handling and the interpretation of antibody tests are separate subjects, and deserve separate explanations.
Where does mescreen™ fit, and where does it not?
mescreen™ belongs to a different category: its current UAE product page describes an at-home mitochondrial function assessment using a dried blood spot sample and laboratory analysis. The page describes wellbeing and performance tracking, with samples shipped to a partner laboratory in the United States, and states that the service is not intended to diagnose, treat or cure a medical condition.
That scope does not make it a substitute for investigating food-related symptoms. If you are considering mitochondrial wellness profiling for its stated purpose, read the UAE assessment's scope and process before deciding whether it matches your question. No food intolerance or allergy diagnosis is being offered here.
Limitations
This article cannot establish why an individual has symptoms, interpret a test result or select a dietary intervention. The CSACI statement dates from 2012; it should be read alongside newer evidence rather than treated as a summary of every subsequent study.
The 2025 IBS trial00328-2/fulltext) addresses a specific intervention and does not establish the diagnostic accuracy of all retail panels or their usefulness in a general UAE population. This article does not verify the performance, licensing, insurance coverage or price of any local food-testing service. It makes no claim that a UAE authority endorses mescreen™ or any testing approach.

For suspected food-related symptoms, the appropriate next step is a discussion with a licensed clinician about the history and the clinical question, rather than interpreting a panel alone. That reflects the history-led assessment described in the EAACI guideline, not a personalised testing or dietary recommendation.
Sources
- CSACI Position statement on the testing of food-specific IgG, Allergy, Asthma & Clinical Immunology, 2012.
- EAACI guidelines on the diagnosis of IgE-mediated food allergy, Allergy, 2023.
- A Novel, IBS-Specific IgG ELISA-Based Elimination Diet in Irritable Bowel Syndrome: A Randomized, Sham-Controlled Trial, Gastroenterology, 202500328-2/fulltext).
- Mescreen Mitochondrial Function Assessment, mescreen™ UAE.